Discovery of small molecule CD40-TRAF6 inhibitors

Journal of Chemical Information and Modeling

Volumn 55, Issue 2, 2015, Pages 294-307

  Zarzycka, Barbara ^a   Seijkens, Tom ^b   Nabuurs, Sander B ^c,d   Ritschel, Tina ^d   Grommes, Jochen ^e   Soehnlein, Oliver ^f   Schrijver, Roy ^a   Van Tiel, Claudia M ^b   Hackeng, Tilman M ^a   Weber, Christian ^f   Giehler, Fabian ^g   Kieser, Arnd ^g   Lutgens, Esther ^b,f   Vriend, Gert ^d   Nicolaes, Gerry A F ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Lead Pharma Medicine   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; DISEASES;

ADAPTER PROTEINS; DRUG DEVELOPMENT; IN-VIVO EXPERIMENTS; INFLAMMATORY DISEASE; RECEPTOR COMPLEX; SIGNALING PATHWAYS; SMALL MOLECULES; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTORS;

LEAD COMPOUNDS;

ANTIINFLAMMATORY AGENT; CD40 ANTIGEN; LIGAND; MOLECULAR LIBRARY; PEPTIDE FRAGMENT; PROTEIN BINDING; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CHEMICAL DATABASE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; GENETICS; HIGH THROUGHPUT SCREENING; INFLAMMATION; MALE; METABOLISM; MOLECULAR DOCKING; MOLECULAR LIBRARY; MOUSE; PERITONITIS; PROCEDURES; SEPSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD40; CELL LINE; DATABASES, CHEMICAL; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; INFLAMMATION; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PEPTIDE FRAGMENTS; PERITONITIS; PROTEIN BINDING; SEPSIS; SMALL MOLECULE LIBRARIES; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 84923377424     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci500631e     Document Type: Article

References (57)

1. Schönbeck, U.; Libby, P. The CD40/CD154 Receptor/ligand Dyad Cell. Mol. Life Sci. 2001, 58, 4-43
2. Arron, J. R.; Pewzner-Jung, Y.; Walsh, M. C.; Kobayashi, T.; Choi, Y. Regulation of the Subcellular Localization of Tumor Necrosis Factor Receptor-Associated Factor (TRAF)2 by TRAF1 Reveals Mechanisms of TRAF2 Signaling J. Exp. Med. 2002, 196, 923-934
3. Zapata, J. M. TNF-Receptor-Associated Factors as Targets for Drug Development Expert Opin. Ther. Targets 2003, 7, 411-425
4. Desideri, G.; Ferri, C. Effects of Obesity and Weight Loss on Soluble CD40L Levels JAMA, J. Am. Med. Assoc. 2003, 289, 1781-1782
5. Kuwana, M.; Nomura, S.; Fujimura, K.; Nagasawa, T.; Muto, Y.; Kurata, Y.; Tanaka, S.; Ikeda, Y. Effect of a Single Injection of Humanized Anti-CD154 Monoclonal Antibody on the Platelet-Specific Autoimmune Response in Patients with Immune Thrombocytopenic Purpura Blood 2004, 103, 1229-1236
6. Boumpas, D. T.; Furie, R.; Manzi, S.; Illei, G. G.; Wallace, D. J.; Balow, J. E.; Vaishnaw, A. BG9588 Lupus Nephritis Trial Group. A Short Course of BG9588 (anti-CD40 Ligand Antibody) Improves Serologic Activity and Decreases Hematuria in Patients with Proliferative Lupus Glomerulonephritis Arthritis Rheum. 2003, 48, 719-727
7. Davis, J. C.; Totoritis, M. C.; Rosenberg, J.; Sklenar, T. A.; Wofsy, D. Phase I Clinical Trial of a Monoclonal Antibody against CD40-Ligand (IDEC-131) in Patients with Systemic Lupus Erythematosus J. Rheumatol. 2001, 28, 95-101
8. Silvian, L. F.; Friedman, J. E.; Strauch, K.; Cachero, T. G.; Day, E. S.; Qian, F.; Cunningham, B.; Fung, A.; Sun, L.; Shipps, G. W.; Su, L.; Zheng, Z.; Kumaravel, G.; Whitty, A. Small Molecule Inhibition of the TNF Family Cytokine CD40 Ligand through a Subunit Fracture Mechanism ACS Chem. Biol. 2011, 6, 636-647
9. Kawai, T.; Andrews, D.; Colvin, R. B.; Sachs, D. H.; Cosimi, A. B. Thromboembolic Complications after Treatment with Monoclonal Antibody against CD40 Ligand Nat. Med. 2000, 6, 114
10. Lutgens, E.; Lievens, D.; Beckers, L.; Wijnands, E.; Soehnlein, O.; Zernecke, A.; Seijkens, T.; Engel, D.; Cleutjens, J.; Keller, A. M.; Naik, S. H.; Boon, L.; Oufella, H. A.; Mallat, Z.; Ahonen, C. L.; Noelle, R. J.; de Winther, M. P.; Daemen, M. J.; Biessen, E. A.; Weber, C. Deficient CD40-TRAF6 Signaling in Leukocytes Prevents Atherosclerosis by Skewing the Immune Response toward an Antiinflammatory Profile J. Exp. Med. 2010, 207, 391-404
11. Chatzigeorgiou, A.; Seijkens, T.; Zarzycka, B.; Engel, D.; Poggi, M.; van den Berg, S.; van den Berg, S.; Soehnlein, O.; Winkels, H.; Beckers, L.; Lievens, D.; Driessen, A.; Kusters, P.; Biessen, E.; Garcia-Martin, R.; Klotzsche-von Ameln, A.; Gijbels, M.; Noelle, R.; Boon, L.; Hackeng, T.; Schulte, K.-M.; Schulte, K.; Xu, A.; Vriend, G.; Nabuurs, S.; Chung, K.-J.; Willems van Dijk, K.; Rensen, P. C. N.; Gerdes, N.; de Winther, M.; Block, N. L.; Schally, A. V.; Weber, C.; Bornstein, S. R.; Nicolaes, G.; Chavakis, T.; Lutgens, E. Blocking CD40-TRAF6 Signaling Is a Therapeutic Target in Obesity-Associated Insulin Resistance Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 2686-2691
12. Ye, H.; Arron, J. R.; Lamothe, B.; Cirilli, M.; Kobayashi, T.; Shevde, N. K.; Segal, D.; Dzivenu, O. K.; Vologodskaia, M.; Yim, M.; Du, K.; Singh, S.; Pike, J. W.; Darnay, B. G.; Choi, Y.; Wu, H. Distinct Molecular Mechanism for Initiating TRAF6 Signalling Nature 2002, 418, 443-447
13. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J.; Meyer, E. F.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: A Computer-Based Archival File for Macromolecular Structures J. Mol. Biol. 1977, 112, 535-542
14. Krieger, E.; Koraimann, G.; Vriend, G. Increasing the Precision of Comparative Models with YASARA NOVA-A Self-Parameterizing Force Field Proteins 2002, 47, 393-402
15. Hooft, R. W.; Sander, C.; Vriend, G. Positioning Hydrogen Atoms by Optimizing Hydrogen-Bond Networks in Protein Structures Proteins 1996, 26, 363-376
16. Vriend, G.; Sander, C. Detection of Common Three-Dimensional Substructures in Proteins Proteins 1991, 11, 52-58
17. Dunbrack, R. L.; Cohen, F. E. Bayesian Statistical Analysis of Protein Side-Chain Rotamer Preferences Protein Sci. Publ. Protein Soc. 1997, 6, 1661-1681
18. An, J.; Totrov, M.; Abagyan, R. Pocketome via Comprehensive Identification and Classification of Ligand Binding Envelopes Mol. Cell. Proteomics 2005, 4, 752-761
19. Laurie, A. T. R.; Jackson, R. M. Q-SiteFinder: An Energy-Based Method for the Prediction of Protein-Ligand Binding Sites Bioinformatics 2005, 21, 1908-1916
20. ChemBridge Corp. San Diego CA USA Www.chembridge.com.
21. Lagorce, D.; Sperandio, O.; Galons, H.; Miteva, M. A.; Villoutreix, B. O. FAF-Drugs2: Free ADME/tox Filtering Tool To Assist Drug Discovery and Chemical Biology Projects BMC Bioinf. 2008, 9, 396
22. Rishton, G. M. Nonleadlikeness and Leadlikeness in Biochemical Screening Drug Discovery Today 2003, 8, 86-96
23. Miteva, M. A.; Violas, S.; Montes, M.; Gomez, D.; Tuffery, P.; Villoutreix, B. O. FAF-Drugs: Free ADME/tox Filtering of Compound Collections Nucleic Acids Res. 2006, 34, W738-W744
24. Hawkins, P. C. D.; Skillman, A. G.; Warren, G. L.; Ellingson, B. A.; Stahl, M. T. Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database J. Chem. Inf. Model. 2010, 50, 572-584
25. Miteva, M. A.; Lee, W. H.; Montes, M. O.; Villoutreix, B. O. Fast Structure-Based Virtual Ligand Screening Combining FRED, DOCK, and Surflex J. Med. Chem. 2005, 48, 6012-6022
26. Du, J.; Bleylevens, I. W. M.; Bitorina, A. V.; Wichapong, K.; Nicolaes, G. A. F. Optimization of Compound Ranking for Structure-Based Virtual Ligand Screening Using an Established FRED-Surflex Consensus Approach Chem. Biol. Drug Des. 2014, 83, 37-51
27. McGann, M. FRED Pose Prediction and Virtual Screening Accuracy J. Chem. Inf. Model. 2011, 51, 578-596
28. ChemBridge Corp. www.hit2lead.com (accessed January 2015).
29. Jain, A. N. Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine J. Med. Chem. 2003, 46, 499-511
30. Tanimoto, T. T. IBM Internal Report, November 17, 1957.
31. Wood, D. J.; de Vlieg, J.; Wagener, M.; Ritschel, T. Pharmacophore Fingerprint-Based Approach to Binding Site Subpocket Similarity and Its Application to Bioisostere Replacement J. Chem. Inf. Model. 2012, 52, 2031-2043
32. Nabuurs, S. B.; Wagener, M.; de Vlieg, J. A Flexible Approach to Induced Fit Docking J. Med. Chem. 2007, 50, 6507-6518
33. Carlsen, H.; Moskaug, J. Ø.; Fromm, S. H.; Blomhoff, R. In Vivo Imaging of NF-Kappa B Activity J. Immunol. Baltim. Md 1950 2002, 168, 1441-1446
34. Shkoda, A.; Town, J. A.; Griese, J.; Romio, M.; Sarioglu, H.; Knöfel, T.; Giehler, F.; Kieser, A. The Germinal Center Kinase TNIK Is Required for Canonical NF-B and JNK Signaling in B-Cells by the EBV Oncoprotein LMP1 and the CD40 Receptor PLoS Biol. 2012, 10, e1001376
35. De Jong, S. J.; Albrecht, J.-C.; Giehler, F.; Kieser, A.; Sticht, H.; Biesinger, B. Noncanonical NF-B Activation by the Oncoprotein Tio Occurs through a Nonconserved TRAF3-Binding Motif Sci. Signal 2013, 6, ra27
36. BIACORE AB. Kinetics and Affinity Analysis Using BIA-Level 1, 1997.
37. Grommes, J.; Vijayan, S.; Drechsler, M.; Hartwig, H.; Mörgelin, M.; Dembinski, R.; Jacobs, M.; Koeppel, T. A.; Binnebösel, M.; Weber, C.; Soehnlein, O. Simvastatin Reduces Endotoxin-Induced Acute Lung Injury by Decreasing Neutrophil Recruitment and Radical Formation PloS One 2012, 7, e38917
38. Seeliger, D.; de Groot, B. L. Conformational Transitions upon Ligand Binding: Holo-Structure Prediction from Apo Conformations PLoS Comput. Biol. 2010, 6, e1000634
39. Sperandio, O.; Miteva, M. A.; Segers, K.; Nicolaes, G. A. F.; Villoutreix, B. O. Screening Outside the Catalytic Site: Inhibition of Macromolecular Inter-Actions Through Structure-Based Virtual Ligand Screening Experiments Open Biochem. J. 2008, 2, 29-37
40. Segers, K.; Sperandio, O.; Sack, M.; Fischer, R.; Miteva, M. A.; Rosing, J.; Nicolaes, G. A. F.; Villoutreix, B. O. Design of Protein-membrane Interaction Inhibitors by Virtual Ligand Screening, Proof of Concept with the C2 Domain of Factor V Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 12697-12702
41. Charifson, P. S.; Corkery, J. J.; Murcko, M. A.; Walters, W. P. Consensus Scoring: A Method for Obtaining Improved Hit Rates from Docking Databases of Three-Dimensional Structures into Proteins J. Med. Chem. 1999, 42, 5100-5109
42. Life Chemicals. http://www.lifechemicals.com/ (accessed August 4, 2014).
43. Bergmann, E. D.; Ginsburg, D.; Pappo, R. The Michael Reaction. In Organic Reactions; John Wiley & Sons, Inc.: New York, 2004.
44. Gold, J. A.; Parsey, M.; Hoshino, Y.; Hoshino, S.; Nolan, A.; Yee, H.; Tse, D. B.; Weiden, M. D. CD40 Contributes to Lethality in Acute Sepsis: In Vivo Role for CD40 in Innate Immunity Infect. Immun. 2003, 71, 3521-3528
45. Ban, T. A. The Role of Serendipity in Drug Discovery Dialogues Clin. Neurosci. 2006, 8, 335-344
46. Hol, W. G. J. Protein Crystallography and Computer Graphics Toward Rational Drug Design Angew. Chem., Int. Ed. Engl. 1986, 25, 767-778
47. Villoutreix, B. O.; Eudes, R.; Miteva, M. A. Structure-Based Virtual Ligand Screening: Recent Success Stories Comb. Chem. High Throughput Screening 2009, 12, 1000-1016
48. Seifert, M. H. J.; Lang, M. Essential Factors for Successful Virtual Screening Mini-Rev. Med. Chem. 2008, 8, 63-72
49. Baell, J. B.; Holloway, G. A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays J. Med. Chem. 2010, 53, 2719-2740
50. Park, B. K.; Boobis, A.; Clarke, S.; Goldring, C. E. P.; Jones, D.; Kenna, J. G.; Lambert, C.; Laverty, H. G.; Naisbitt, D. J.; Nelson, S.; Nicoll-Griffith, D. A.; Obach, R. S.; Routledge, P.; Smith, D. A.; Tweedie, D. J.; Vermeulen, N.; Williams, D. P.; Wilson, I. D.; Baillie, T. A. Managing the Challenge of Chemically Reactive Metabolites in Drug Development Nat. Rev. Drug Discovery 2011, 10, 292-306
51. Solca, F.; Dahl, G.; Zoephel, A.; Bader, G.; Sanderson, M.; Klein, C.; Kraemer, O.; Himmelsbach, F.; Haaksma, E.; Adolf, G. R. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker J. Pharmacol. Exp. Ther. 2012, 343, 342-350
52. 50 Data-A Statistical Analysis PloS One 2013, 8, e61007
53. Karin, M.; Yamamoto, Y.; Wang, Q. M. The IKK NF-Kappa B System: A Treasure Trove for Drug Development Nat. Rev. Drug Discovery 2004, 3, 17-26
54. Sheng, Y.; Saridakis, V.; Sarkari, F.; Duan, S.; Wu, T.; Arrowsmith, C. H.; Frappier, L. Molecular Recognition of p53 and MDM2 by USP7/HAUSP Nat. Struct. Mol. Biol. 2006, 13, 285-291
55. Xie, P. TRAF Molecules in Cell Signaling and in Human Diseases J. Mol. Signal. 2013, 8, 7
56. Guédat, P.; Colland, F. Patented Small Molecule Inhibitors in the Ubiquitin Proteasome System BMC Biochem. 2007, 8 (Suppl 1) S14
57. Wu, H.; Arron, J. R. TRAF6, a Molecular Bridge Spanning Adaptive Immunity, Innate Immunity and Osteoimmunology BioEssays 2003, 25, 1096-1105